Objective-Prokineticins are potent angiogenic hormones that use 2 receptors, prokineticin receptor-1 (PKR1) and PKR2, with important therapeutic use in anticancer therapy. Observations of cardiac and renal toxicity in cancer patients treated with antiangiogenic compounds led us to explore how PKR1 signaling functioned in heart and kidney in vivo. Methods and Results-We generated mice with a conditional disruption of the PKR1 gene. We observed that PKR1 loss led to cardiomegaly, severe interstitial fibrosis, and cardiac dysfunction under stress conditions, accompanied by renal tubular dilation, reduced glomerular capillaries, urinary phosphate excretion, and proteinuria at later ages. Abnormal mitochondria and increased apoptosis were evident in both organs. Perturbation of capillary angiogenesis in both organs was restored at the adult stage potentially via upregulation of hypoxia-inducible factor-1 and proangiogenic factors. Compensatory mechanism could not revoke the epicardial and glomerular capillary networks, because of increased apoptosis and reduced progenitor cell numbers, consistent with an endogenous role of PKR1 signaling in stimulating epicardinϩ progenitor cell proliferation and differentiation. Conclusion-Here, we showed for the first time that the loss of PKR1 causes renal and cardiac structural and functional changes because of deficits in survival signaling, mitochondrial, and progenitor cell functions in found both organs. (Arterioscler Thromb Vasc Biol. 2011;31:842-850.)
P athological angiogenesis is characterized by either excessive (eg, cancer) or inadequate (eg, coronary artery disease) neovascularization. Identification of molecular and cellular components involved in promoting or inhibiting angiogenesis is emerging to develop angiogenesis based treatments.
Prokineticins 1 (also called endocrine gland [EG]-vascular endothelial growth factor [EG-VEGF]) and 2 (also called Bv8) have been identified as potent angiogenic factors. These 2 secreted proteins from the AVIT secreted protein family are widely distributed in mammalian tissues and human blood cells. 1 In addition to being strong angiogenic factors, 2 prokineticins act as survival/mitogenic factors in various cells, including endothelial cells, 3 neuronal cells, 4 lymphocytes and hematopoietic stem cells, 5 and cardiomyocytes. 6 They exert their biological effects by stimulating 2 closely related receptors, prokineticin receptor-1 (PKR1) and PKR2. 7, 8 Prokineticin-2 is the most potent agonist of both these receptors. 9, 10 Both receptors use the various G protein signaling pathways and are ubiquitously expressed in mammalian tissues. 7, 8, 10 Aberrant prokineticin signaling may also cause hypervascularity in various tissues and is strongly associated with the development of polycystic ovary syndrome 11 ; neuroblastoma 12 ; and colorectal, testicular, and prostate cancer. 13 It has recently been demonstrated that prokineticin-2 is secreted by tumorinfiltrating myeloid cells and strongly promotes tumor angiogenesis. Antiprokineticin-2 treatment significantly decreases myeloid cell mobilization, thereby inhibiting tumor growth 14 Thus, the use of immunoneutralizing antibodies or antagonists of prokineticin-2 and its receptors may be a useful strategy for cancer treatment. However, antiangiogenesis treatments targeting platelet-derived growth factor (PDGF), VEGF and its receptors, or receptor thyrosine kinase signaling have been associated with clinical renal and cardiac toxicity. [15] [16] [17] [18] Thus, antiangiogenesis treatment-related cardiovascular and renal side effects and impaired tissue repair increase the risk of heart and kidney failure in cancer patients. However, little is known about the role of PKR1 signaling in the kidney and cardiovascular system. 18 The low levels of PKR1 and prokineticin-2 transcripts and proteins in cardiac samples from humans with end-stage heart failure suggest that prokineticin-2/PKR1 signaling is particularly important in the heart. 6 Intracardiac transient PKR1 gene transfer decreases mortality rate and preserves left ventricular (LV) function by promoting angiogenesis and cardiomyocyte survival in a mouse model of myocardial infarction. 6 Interestingly, PKR1 overexpression in mouse heart does not lead to spontaneous abnormalities in cardiomyocytes but to an increase in capillary density and the number of coronary arterioles. 19 Cardiac PKR1 signaling leads to the upregulation of the ligand of this receptor, prokineticin-2, as a paracrine factor inducing the proliferation and differentiation of epicardinϩ, epicardium-derived progenitor cells, thereby regulating postnatal coronary angiogenesis and vasculogenesis. 19 PKR1 signaling via Akt protects cardiomyocytes, 6 as well as endothelial cells, 20 against apoptosis. A divergent role of prokineticin-2 in endothelial cells has recently been described, with the activation of PKR1 signaling promoting angiogenesis and the activation of PKR2 inducing fenestration in endothelial cells. 21 On the basis of the occurrence of cardiac and renal conditions in patients treated with angiogenesis inhibitors, we hypothesized that PKR1 signaling might play a key role in heart and kidney function. We show here that the loss of PKR1 causes structural and functional changes in the kidney and heart reminiscent of adverse cardiovascular and renal events induced by treatments inhibiting angiogenesis.
Methods

Generation of Knockout Mice
For conditional disruption of the GPR73 gene encoding PKR1, mice transgenic for the germline null allele of PKR1 were generated in the transgenic core facility of the Mouse Clinical Institute, Illkirch, France, as previously described (Supplemental Material, available online at http://atvb.ahajournals.org). 19 Loss of PKR1 in heart and kidney was verified at the transcriptional and protein levels. The PKR2 mRNA expression remained unchanged in heart and kidney (Supplemental Figure I ). All animal experimentation was performed in accordance with institutional guidelines of the French Animal Care Committee, with European regulation-approved protocols. Unless otherwise mentioned, analyses were performed on mice aged 24 weeks.
Histological and Electron Microscopy Analyses
Hearts were removed from neonatal or 24-week-old mice, dissected, and frozen for the cutting of frozen sections (10 m), which were stained with Mallory tetrachrome. 6, 19 
Echocardiography and Hemodynamic Assessment
Systolic function in 24-week-old male mice (nϭ12) was assessed by echocardiography in M-mode (Sonos 5500, Hewlett-Packard, with a 15-MHz linear transducer) and 2-dimensional measurements 19 (Supplemental Material).
Isolation of Cardiomyocytes
Ventricular cardiomyocytes were isolated from adult mice as previously described. 22
Terminal dUTP Nick-End Labeling (TUNEL) Assay, Immunohistochemistry, and Western Blot Analysis
Terminal dUTP Nick-End Labeling (TUNEL) assays, immunofluorescence, Oil Red O staining, and Western blot analyses were performed according to the manufacturer's instructions (Supplemental Material). 6, 19 The intensity of staining of each section was quantified with ImageJ software.
RNA Extraction, Quantification, and Reverse Transcription-Polymerase Chain Reaction Analysis
Total RNA was isolated from neonatal and adult mouse hearts and kidneys with TRI Reagent (Molecular Research Center) and treated with DNase, using the RNase-Free DNase Set, as previously described. 19 Primer sequences are shown in Supplemental Table I .
In Situ Hybridization
Serial cryosections (10 m) were collected on gelatin-coated (Superfrost Plus, Kindler) slides. In situ hybridization was performed as described in the gene expression section of the EMPReSS web site (http://empress.har.mrc.ac.uk/browser) 23 (see Supplemental Material).
Biochemical Analyses on Blood and Urine Samples
Blood and urine samples were collected and analyzed as outlined on the EMPReSS web site (http://www.empress.har.mrc.ac.uk) (see Supplemental Material). 24
Kidney Explants and Isolation of Epicardin؉ Progenitor Cells
Renal explants and neonatal renal-epicardium-derived progenitor cell cultures were performed as previously described for cardiac explants and cardiac-epicardium-derived progenitor cell cultures (Supplemental Material).
Statistical Analysis
Data are expressed as meansϮSEM. Multigroup comparisons were carried out by 1-way ANOVA with post hoc correction. The Student t test was used for pairwise comparisons between groups. For all analyses, values of PϽ0.05 were considered significant.
Results
PKR1-Null Mutant Mice Display Histological and Morphological Alterations to the Heart
Mutant mice developed dilated cardiomyopathy, as demonstrated by the presence of cardiomegaly and chamber enlargement ( Figure 1A and 1B). Mallory tetrachrome staining revealed a severe interstitial fibrosis (blue), cellular disorganization, and an abnormal alignment of myofibers in the epicardial and subepicardial area of mutant hearts ( Figure  1C ). A corresponding decrease in LV mass was also detected in mutant hearts ( Figure 1D ). The ratio of heart weight with blood in the ventricular cavities to body weight was slightly but significantly (PϽ0.05) higher in mutant mice (6.1Ϯ0.01 mg/g, nϭ6) than in wild-type mice (5.3Ϯ0.01 mg/g, nϭ6). Reverse transcription-polymerase chain reaction analysis of mRNA from the hearts of 24-week-old mutant mice showed the levels of expression of the collagen 1a1 and 1a2 genes to be particularly high in mutant mice, consistent with the development of severe cardiac fibrosis (Supplemental Figure  IIB) . A reduced level of the contractile sarcomeric protein troponin C was evident in the mutant hearts (Supplemental Figure IIC ). No changes in expression levels of intracellular Ca 2ϩ cycling genes were observed in mutant hearts (Supplemental Figure III ).
Morphometric analysis confirmed that isolated cardiomyocytes from 24-week-old mutant hearts were significantly (33%) larger than those from wild-type hearts ( Figure 1E ). Mean cardiomyocyte length was 405.3Ϯ16.7 m for the wild-type and 512.09Ϯ22.7 m for the mutant (nϭ420, PϽ0.001). Dystrophin staining of cryosectioned hearts confirmed an increase in cardiomyocyte length (Supplemental Figure II) . Thus, PKR1-null mice develop physiologically significant, but compensated, moderate dilated cardiomyopathy.
PKR1 Deficiency-Induced Cardiac Dysfunction
Echocardiographic analysis revealed a significant decrease in interventricular septal thickness and LV posterior wall thickness was observed in mutants ( Supplemental Table II ). LV end-diastolic and end-systolic dimensions under basal conditions did not differ significantly between mutant and wildtype mice. However, in conditions of stress, such as the response to ␤1-adrenergic stimuli (dobutamine injection), mutant mice displayed significantly a reduction in fractional shortening and in ejection fraction ( Figure 1F ). An increase in both LV end-diastolic and end-systolic dimensions was observed after dobutamine treatment. No change in expression of the ␤1-adrenergic receptor was detected in mutant hearts, ruling out the possibility of changes in the ␤-adrenergic sensitivity of the heart (Supplemental Figure III) . The clinical course of the disease was analyzed by examining mutant hearts at neonatal stages (P1). Histological analyses provided evidence of dilated cardiomyopathy in neonatal mutant hearts (nϭ6, Figure 1G ).
PKR1 Deficiency-Induced Cardiac Dysfunction Is Associated With Abnormal Mitochondrial Structure and Function and an Increase in Apoptosis
Electron microscopy showed that the hearts of 24-week-old mutants had a thin epicardium with an abnormal subepicardial accumulation of cardiomyocytes and high levels of collagen deposition (Figure 2A ). The mutant cardiomyocytes had undulating cellular membranes and displayed focal myofibril disorganization, a decrease in sarcomere length and aberrant mitochondria, myocyte fragmentation, a modified distribution of mitochondria between myofibrils, and myofibril disarray ( Figure 2B ). Staining for a cell adhesion molecule, N-cadherin, confirmed the disassembly of intercalated disc structures and abnormal structure of the mutant heart. Furthermore, mutant hearts had more mitochondria than wild-type hearts, and these mitochondria were densely packed and appeared to be fused ( Figure 2B ). Mitochondrial function was assessed by carrying out a histochemical analysis of the enzymes involved in respiratory chain function, such as succinic dehydrogenase, and Oil Red O staining. Succinate dehydrogenase (SDH) activity in the subepicardial area of mutant hearts was significantly lower than that in wild-type hearts, consistent with the defects observed in mitochondrial morphology ( Figure 2C ). Oil Red O staining showed that mutant myocytes contained larger numbers of lipid droplets, with levels of lipid accumulation within these cells 3 times higher than in the wild-type ( Figure 2D ).
To investigate the role of programmed cell death in the dilated cardiomyopathy of the mutants, we carried out TUNEL analyses on heart sections from mutant and wild-type mice ( Figure 2E ). The abundance of TUNEL-positive epicardial and myocardial cells (green) was detected in the mutant hearts.
PKR1 Deficiency-Induced Renal Abnormalities Accompanied Apoptosis and Reduced Capillary Lumen in Glomeruli
Macroscopic inspection showed the kidneys of mutant mice to be massively enlarged, with an irregular surface presenting multiple cortical swellings ( Figure 3A ). In some cases, 1 kidney was atrophied or displayed massive urine retention ( Figure 3A and 3B) . Overall, the ratio of kidney weight with urine in the cortical swellings to body weight significantly increased in PKR1-null mice as compared with wild-type mice at the age of 24 weeks ( Figure 3C ). We also examined neonatal kidneys to determine the clinical course of the disease. Kidney hypoplasia was also evident in neonatal mutants ( Figure 3D ). TUNEL assays in kidney sections from mutant and wild-type mice revealed that the glomeruli of mutant kidneys contained significantly more TUNELpositive cells (green) than those of wild-type kidneys, at the age of 24 weeks ( Figure 3E ). Accordingly, mutant glomeruli contained fewer platelet endothelial cell adhesion molecule-1-positive visible capillary endothelial cells ( Figure 3F ).
Renal Ultrastructural Analysis and Abnormal Mitochondria
Systematic histological examinations of mutant mice showed dilatation of the Bowman's spaces in glomeruli ( Figure 4A , upper panels). Electron micrographs showed considerable thickening of the lamina densa of the glomerular basement membrane, with the presence of numerous protrusions on the podocytic side ( Figure 4A , lower panels). Mallory tetrachrome staining revealed dilated renal tubules and severe interstitial fibrosis between the tubules ( Figure 4B , upper panels). In the mutant kidney, peritubular capillaries were occupied by structures with multiple lumens and prominent interstitial cells, often in loose associations, corresponding to dysmorphogenic capillaries ( Figure 4B , middle panels). The number and density of mitochondria in proximal tubule cells were significantly lower in mutant animals than in wild-type animals. These abnormalities in mitochondrial density were accompanied by changes in mitochondrial structure, such as mitochondrial swelling, and decreases in the numbers of cristae and granulocytes ( Figure 4C , lower panels). Consis- tent with the observed defects in mitochondrial morphology, mutant kidneys displayed only 75% of the SDH activity of wild-type kidneys (nϭ6, Figure 4D ).
PKR1 Deficiency-Induced Renal Dysfunction
Renal functions of 24-week-old mice were assessed by blood and urine chemistry. The 24-hour urine flow of mutant mice was significantly lower than that of wild-type mice. However, no differences in water and food intake and blood glucose levels were observed (Table) . No significant changes in urinary potassium, sodium, and chloride excretion rates were observed between mutant and wild-type mice, consistent with the values obtained for serum (Table) . Mutant mice had a significantly lower glomerular filtration rate, as estimated by creatinine clearance. Lower creatinine concentrations (mmol/ 24-hour per g) in the urine of mutant mice were associated with higher concentrations in the serum of these mice. However, the urine phosphate/creatinine ratio but not calcium/creatinine ratio was significantly higher in mutant mice than in wild-type controls. Mutant mice displayed higher levels of absolute renal phosphate excretion, associated with hypophosphatemia (Table) , indicating that mutant mice displayed poor absolute renal phosphate retention in the kidney and poor stabilization of serum absolute renal phosphate concentration. Note that mutant mice exhibit protein urea at the age of 36 weeks (total proteins in urine were 6.625Ϯ0.7 and 10.72Ϯ2.4 g/L for wild-type and mutant, respectively, nϭ5, PϽ0.05), consistent with fenestrated endothelial cell structures at this age (Supplemental Figure VIC) .
Characterization of Cardiac and Renal Function Impairment
We determined the potential defect in vascularization by determining the numbers of PECAM-1ϩcapillary density in hearts and kidneys. Neonatal PKR1-null mutant mice exhibit reduced numbers of capillary number and density as detected by PECAM-1 staining in the heart and kidneys compared with their wild-type littermates ( Figure 5A ). However, at the age of 24 weeks, no difference in the level of angiogenesis was observed in the mutant hearts and kidneys at the expense of epicardial and glomerular zones compared with wild-type hearts and kidneys (Supplemental Figure IV) . A reduction of angiogenesis was observed in mutant epicardium by 12% (nϭ4, PϽ0.05) and in mutant glomerulus by 39% (nϭ4, PϽ0.05). Hypoxia-inducible factor-1␣ (HIF-1␣) transcript levels were significantly increased in the mutant hearts but not in the kidneys at the postnatal day 1. However, at the age of 3 weeks, inductions of HIF-1 ␣ transcript and protein were observed in both heart and kidneys of mutants ( Figure 5B and 5C). Parallel to HIF-1␣ induction at this age, the proangiogenic factors PDGF-B and fibroblast growth factor-2 transcripts were increased in both mutant heart and kidneys. VEGF transcripts were enhanced slightly in the heart but significantly in the kidneys of the mutants ( Figure 5D ). These data indicate the initiation of compensatory signaling at these time points. Next, we investigated whether the PKR1 survival pathway is impaired in the 3-week-old mice hearts and kidneys. Indeed, activation of Akt kinase appeared reduced in mutant both kidneys and hearts compared with wild-type, indicated by 60% or greater reductions in phospho-Akt ( Figure 5E) , confirming the increased cell death in these organs at the early stage. Costaining of the apoptotic marker active caspase-3 and cell-specific markers illustrated that cardiomyocytes (troponinϩ), epicardial and glomerular progenitor cells (epicardinϩ), and glomerular endothelial cells (PECAMϩ) were also positive for active caspase-3 ( Figure  5F ) only in mutant hearts and kidneys at the age of 24 weeks. These data clearly indicate that the angiogenic defects in the mutant are ameliorated over time but cannot compensate for the survival deficit in these cells. Supporting these findings, we found that the VEGF level was increased in the extraglomerular area but not in the glomerular zone of the mutant kidneys ( Figure 5G) .
Interestingly, epicardinϩ cells in the mutant epicardiumsubepicardium and glomerulus were significantly lower than those in the wild-type tissues ( Figure 6A) . To assess the possible direct effect of PKR1 signaling on renal-epicardinϩ cells as shown for cardiac-epicardinϩ cells, 19 we used explant cultures from wild-type and mutant kidneys from postnatal day 1 (P1). In untreated kidney explants, 50Ϯ6% of the cells proliferate, as shown by Ki67 staining (Figure 6B ). The treatment of kidney explants with prokineticin-2 (5 to 10 nmol/L) stimulated the extensive outgrowth of cells ( Figure 6B, histogram) . Of the emerging epithelial cells, 90% were positive for epicardin (red). Prokineticin-2 induced differentiation of renal-epicardinϩ cells into PECAM-1ϩ endothelial (red) and ␣-smooth muscle actinϩ vascular smooth muscle cells (green) that were blocked in the mutant renal-epicardinϩ cells (Figure 6B , histogram, and Supplemental Figure VA) . Similar results were obtained in epicardinϩ isolated cell cultures derived from kidney explants (Supplemental Figure VB ).
Discussion
Several angiogenic factors have been shown to regulate heart and kidney functions. Mice lacking PDGF-B display renal and cardiovascular abnormalities. 25, 26 VEGF has been shown to be involved in heart development, 27 glomerulogenesis, and tubulogenesis in the kidney. 28 Fibroblast growth factor is also involved in heart development and function 29 and in glomerulus formation. 30 Here, we provide the first evidence that angiogenic PKR1 signaling regulates heart and kidney functions that are correlated with the expression pattern of PKR1 in heart and kidney ( Figure 6 and Supplemental Figure IE) . Acute or chronic dysfunction in the heart or kidney may lead to dysfunction in the other organ, resulting in the cardiorenal syndrome. 31 However, in PKR1-null mutant mice, both organs displayed morphological abnormalities at the neonatal stage, eliminating the possibility of a cardiorenal syndrome. The cardiomyopathy induced by the absence of PKR1 was associated with decreases in LV mass and LV posterior and interseptal diameters, cardiomyocyte elongation, and an increase in apoptosis, together with abnormal mitochondrial structure and function, with no change in indices of cardiac function in basal conditions. However, systolic and diastolic dysfunctions, as determined by measuring the percentage of fractional shortening and ejection fraction, were evident under stress conditions, such as those induced by adrenergic stimuli. Impaired contractility in mutant hearts could result from reduced levels of contractile protein troponin T cardiac, because changes in troponin T cardiac lower contractile force by reducing strong myosin-actin binding in human dilated cardiomyopathy. 32 The lack of increase in arterial blood pressure in PKR1-null mutants compared with wild-type mice (110Ϯ7 and 105Ϯ8 mm Hg, respectively; Supplemental Material) strongly indicates that cardiomyopathy was not a consequence of the hemodynamic alterations responsible for cardiac overloading, instead resulting directly from the loss of PKR1 in the heart.
We show here that PKR1-null mutant mice also developed renal functional abnormalities. Creatinine clearance was weaker in mutant mice than in the wild-type, and mutant mice had a low glomerular filtration rate. Increased thickness of glomerular basement membrane and reduced filtration rates may explain the lower protein levels in the 24-week-old mutants. However, mutant mice exhibit high level of proteinuria at the age of 36 weeks, probably because of progressive glomerular endothelial dysfunction 33 (Supplemental Figure  VIC) . Ablation of PKR1 resulted in the enlargement of tubules and an increase in the excretion of phosphate into urine. The effects of PKR1 loss-of-function on urinary phosphate excretion were accompanied by hypophosphatemia. It is clear that the hypercreatinemia in mutant mice resulted from the hypoexcretion of creatinine. PKR1 ablation did not cause a renal calcium leak, eliminating the possibility of coordinated effects of bone formation and the renal conservation of calcium and phosphate. Our findings raise the possibility that abnormal mitochondrial structure and low oxidative capacity of the mitochondria in mutant mice accelerate the onset of the observed cardiac and renal abnormalities and may trigger a subset of apoptotic signals and adaptive mechanisms for the inhibition of angiogenesis. Recent reports have demonstrated that mitochondrial dysfunction is involved in either the etiology or the underlying pathological feature of various renal diseases 34 and is a major cause of cardiac dysfunction. 35 Profound reductions in Akt activation might increase mitochondrial apoptosis, possibly accounting for the loss of epicardial cells and cardiomyocytes in the mutant hearts, leading to the thinning of the ventricular wall. The kidney cortex in PKR1 mutant mice appeared thinner than that of wild-type mice as a consequence of urinary retention, which is consistent with the lower Akt activity and increased apoptosis. The data presented here are the first in vivo report that PKR1 signaling prevents apoptosis in cardiomyocytes, epicardium, and glomerular endothelial and progenitor cells consistent with the previous in vitro findings that PKR1 via activates Akt signaling, protecting cardiomyocytes 6 and endothelial cells 20 against the induction of apoptosis by hypoxic stimuli. Prokineticins via PKR1 also serve as survival factors for corpus luteum-derived and bovine aortic and human placental endothelial cell and umbilical vein-derived macrovascular endothelial cells. 20, 21 Neonatal and 3-week-old PKR1 mutant mice have fewer capillaries than normal in heart and kidney, potentially establishing hypoxic conditions with impaired mitochondrial function. Mitochondrial activity has also been shown to be involved in HIF-1␣ activation in mildly hypoxic conditions. 36 In the mutant heart and kidneys, these defects in angiogenesis were compensated by an increase in HIF-1␣ production accompanying an increase in proangiogenic factors. Interestingly, compensated mechanism revokes the extraepicardial and extraglomerular capillary networks in mutant hearts and kidneys. Interstitial cells and tubular epithelium also provide signals such as VEGF for maintenance of the peritubular capillary network, independent of the glomerular capillary network. 37 Our findings clearly demonstrated that VEGF level indeed was increased in mutant tubular epithelium, possibly restoring extraglomerular angiogenesis. Currently, we are investigating critical components of compensatory angiogenesis in mutant hearts.
Restoration of the angiogenic pathways could not reverse damages in PKR1 mutant hearts and kidneys because of defective survival pathways, such as reduced Akt activity, increased caspase-3 activity, and impaired common progenitor cell functions. Moreover, an abundance apoptotic epicardinϩ cells in mutant epicardium and glomeruli can be considered a failure of endothelial repair mechanisms in epicardial and glomerular angiogenesis. Recently, we have shown that prokineticin-2 via PKR1 induces the proliferation and differentiation of epicardinϩ, cardiac epicardinϩ cells into endothelial and smooth muscle cells, thereby regulating postnatal coronary angiogenesis and vasculogenesis. 19 Renal PϽ0.05) . B, HIF-1␣ transcript levels in RNA derived from neonatal (left) and 3-week-old (right) heart and kidneys (nϭ4, PϽ0.05). C, Western blot analyses with HIF-1␣ and GAPDH antibodies on hearts and kidney protein confirm an increase in HIF-1␣ levels in 3-week-old mutant heart and kidneys (nϭ3, duplicated, PϽ0.05). D, Histogram represents reverse transcription-polymerase chain reaction analysis showing that expression of proangiogenic factors PDGF, fibroblast growth factor (FGF), and VEGF was differently altered in mutant heart and kidneys at the age of 3 weeks (nϭ4). E, Western blot analysis and histogram show that diminished levels of phosphorylated (p-)Akt form in 3-week-old mutant both hearts and kidneys (nϭ4). F, Coimmunostaining of heart and kidney sections with active caspase-3 antibody and cardiomyocyte-specific troponin, endothelium-specific PECAM-1, and progenitor cell-specific epicardin antibodies in cardiomyocytes (cm), epicardium (epi), and glomerulus (glm). G, VEGF immunostaining of glomerulus (glm) and tubules (tbl). epicardinϩ cells may play an important role in vascular remodeling during glomerular development. 38 Epicardin (Pod1)-null mice have been shown to have heart defects and a complex kidney phenotype. 38 Recently, a relationship between the epicardium and the glomerulus was identified, originating in a similar progenitor tissue, 39 and expressing similar genes. 40 We show here that PKR1 signaling controls epicardialϩ progenitor cell differentiation that may be involved in glomerular and epicardial angiogenesis. We currently initiate the cell-specific inactivation of PKR1 in the mouse model to further and fully elaborate the mechanism underlying pathology in PKR1 mutant heart and kidneys.
Several anticancer drugs inhibiting PDGF receptor, VEGF, or multiple receptor tyrosine kinase signaling have recently been associated with cardiac and renal impairments, including proteinuria, hemorrhage, thrombosis, hypertension, and impairment in wound healing and tissue repair. 41, 42 Moreover, the activation or upregulation of other proangiogenic signaling pathways as a form of evasive resistance to angiogenesis inhibitors has been shown to circumvent antiangiogenic treatment, triggering neovascularization in due course. 43, 44 Here we showed that angiogenic PKR1 inhibition provokes cardiac and renal impairments, proteinuria, and rebound development of angiogenesis. PKR1null mutant mice exhibit progressive fibrosis in their remodeling hearts and kidneys, possibly because of hypoxia, which may also drive fibrosis. 45 On the contrary, anti-VEGF therapy reduces fibrosis and collagen deposits in the lungs and the liver with unknown mechanism 46, 47 ; it is not evident that it is due to inhibition of VEGF signaling, because administration of VEGF had a clear therapeutic benefit, slowing the development of renal fibrosis. 48 Note that some of the adverse effects of antiangiogenic therapeutics could be due to off-target effects of the drugs.
Collectively, schematic illustration (Supplemental Figure VII ) shows that PKR1 inactivation in mice leads to deficits in Akt survival signaling, mitochondrial functions, and progenitor cell functions that could be the link between cardiac and renal damage. This study may provide new insight into the pathogenesis of cardiovascular and renal diseases and lead to improvements in the management of adverse effects of antiangiogenic therapy. Figure 6 . A, Epicardinϩ progenitor cells (green) in heart and glomeruli. Magnification, ϫ40. Quantification of epicardin positive cells was calculated as numbers of epicardin positive cells/ 4Ј,6-diamidino-2-phenylindoleϩ (dapiϩ) cells corrected with 100 per high-power field (nϭ5, PϽ0.05). B, Representative illustration of epicardin-, Ki67-, PECAM-1-, and ␣-smooth muscle actin (SMA)-positive cell number in the renal epicardium-derived progenitor cells derived from kidney explants treated with vehicle (veh) or prokineticin-2 (PK-2) (5 or 10 nmol/L) for 24 hours. Magnification, ϫ63. Histograms show the quantitative changes between wild-type (ϩ/ϩ) and null mutants (Ϫ/Ϫ). Quantification of the specific cell number/dapi positive cell number corrected with 100 per high-power field (nϭ4, PϽ0.05).
